logo
logo

Weight-loss startup SheMed raises $50 million in Series A funding to expand across the UK, driven by rising demand for GLP-1 medications.

Oct 23, 2025•4 days ago

Amount Raised

$50 Million

Round Type

series a

LondonHealth Care

Description

London-based startup SheMed has successfully raised $50 million in its Series A round to bolster its operations in the UK. The funds will support new research and initiatives to enhance personalized care for women. Founded in April 2024, SheMed offers tailored weight-loss programs using medications like Wegovy and Mounjaro. The company has already attracted over 60,000 members in its first year.

Company Information

Company

SheMed

Location

London, England, United Kingdom

About

SheMed is a London-based startup that offers personalized weight-loss plans using popular medications such as Wegovy and Mounjaro. Founded in April 2024 by sisters Olivia and Chloe Ferro, the company has quickly gained over 60,000 members in under a year. SheMed combines medication with tailored support and comprehensive health screenings to help women achieve their weight-loss goals. Unlike other telehealth platforms, SheMed uses blood tests to determine qualification for GLP-1 treatment plans.

Related People

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech